ArticleEuropean journal of pediatrics2026
Treatable traits in paediatric bronchiectasis: current practice and a proposed checklist.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We recently published a treatable traits (TT) framework for children with non-cystic fibrosis bronchiectasis (NCFB). Whether these traits are routinely documented as assessed and identified in clinical practice is unknown. We conducted a retrospective study of children (< 18 years) with CT-confirmed NCFB followed at a tertiary referral centre (2010-2024). For each patient, we determined which of 41 predefined TTs across four domains-aetiological (n = 6), pulmonary (n = 15), extrapulmonary (n = 9), and behavioural/environmental (n = 11)-were documented as assessed, and among those assessed, which were identified. Among 121 children (median age 10.1 years; median 2 exacerbations/year), only 20 out of 41 TTs (49%) were documented as assessed per patient, and a median of 6 were identified. Aetiological and pulmonary traits were more frequently documented as assessed than extrapulmonary and behavioural. Anxiety and depression in children or parents, as well as viral prevention measures, were never documented, and treatment adherence was rarely recorded. When traits were documented as assessed, several were frequently identified: neutrophilic inflammation was found in 93%, eosinophilic inflammation in 35%, and short-acting beta-agonist overuse in 47% of assessed patients.
conclusionEven in a tertiary referral centre, half of TTs lacked documented assessment in children with NCFB, particularly psychosocial and behavioural factors. Based on these findings, we propose a pragmatic TT checklist, used as a flexible clinical guide, to support structured, clinically relevant, and traceable assessment of children with NCFB in routine care. WHAT IS KNOWN: • Paediatric non-cystic fibrosis bronchiectasis is a heterogeneous disease requiring individualised management. • A "treatable traits" approach has been proposed to guide precision medicine beyond standard guidelines. WHAT IS NEW: • In real-life paediatric practice, only half of treatable traits are documented as assessed, with psychosocial and behavioural factors particularly infrequently documented. • We propose a pragmatic checklist to support structured, clinically guided assessment and improve routine care.
Indexed as
Identifiers
42184004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.